Testing the drug mirdametinib for brain and spinal cord tumors
Original title: A Study of Mirdametinib in People With Central Nervous System Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early study, so the first goal is to learn if the drug is safe in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a drug called mirdametinib in people with tumors of the brain and spinal cord.
Who this trial is for. This study is for people with central nervous system tumors. That means tumors of the brain and spinal cord. The tumor types listed are glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary and neurohistiocytosis. The study is testing a drug called mirdametinib.
Where it stands. This trial has not reported results. The team wants to learn if mirdametinib is safe for people with these tumors. They also want to learn if it works. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: For now, this is a study, not a treatment you can get from your own doctor. If you have one of these tumor types, you could ask your care team about it. They can tell you if a study like this makes sense for you.
What it doesn't mean: This does not mean the drug is proven. A trial is a test, and the answers are still unknown. Joining a trial does not mean you will be helped. Some people feel no better. This is not a promise of a cure.
Source: ClinicalTrials.gov, September 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.